{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Jonathan M Batchelor, Kim S Thomas, Perways Akram, Jaskiran Azad, Anthony Bewley, Joanne R Chalmers, Seau Tak Cheung, Lelia Duley, Viktoria Eleftheriadou, Robert Ellis, Adam Ferguson, Jonathan MR Goulding, Rachel H Haines, Hamdi Hamad, John R Ingram, Bisola Laguda, Paul Leighton, Nick Levell, Areti Makrygeorgou, Garry D Meakin, Adam Millington, Malobi Ogboli, Amirtha Rajasekaran, Jane C Ravenscroft, Andrew Rogers, Tracey H Sach, Miriam Santer, Julia Stainforth, Wei Tan, Shyamal Wahie, Jennifer White, Maxine E Whitton, Hywel C Williams, Andrew Wright & Alan A Montgomery.

Jonathan M Batchelor ^1,†, Kim S Thomas ^1,*,†, Perways Akram ², Jaskiran Azad ³, Anthony Bewley ⁴, Joanne R Chalmers ¹, Seau Tak Cheung ⁵, Lelia Duley ⁶, Viktoria Eleftheriadou ⁷, Robert Ellis ^8,9, Adam Ferguson ¹⁰, Jonathan MR Goulding ¹¹, Rachel H Haines ⁶, Hamdi Hamad ¹², John R Ingram ¹³, Bisola Laguda ¹⁴, Paul Leighton ¹, Nick Levell ¹⁵, Areti Makrygeorgou ¹⁶, Garry D Meakin ⁶, Adam Millington ¹⁷, Malobi Ogboli ¹⁸, Amirtha Rajasekaran ¹⁹, Jane C Ravenscroft ²⁰, Andrew Rogers ², Tracey H Sach ²¹, Miriam Santer ⁵, Julia Stainforth ²², Wei Tan ⁶, Shyamal Wahie ²³, Jennifer White ⁶, Maxine E Whitton ¹, Hywel C Williams ¹, Andrew Wright ²⁴, Alan A Montgomery ⁶

^* Corresponding author Email: Kim.Thomas@Nottingham.ac.uk

^† Joint first authors

^‡ The full author list can be found in Appendix 1.

Joint first authors

The full author list can be found in Appendix 1.

Declared competing interests of authors: Anthony Bewley reports personal fees from AbbVie Inc. (North Chicago, IL, USA), Almirall SA (Barcelona, Spain), Leo Pharma (Ballerup, Denmark), Galderma SA (Lausanne, Switzerland), Janssen Pharmaceutica (Beerse, Belgium), Novartis Pharmaceuticals (Basel, Switzerland), Eli Lilly and Company (Indianapolis, IN, USA), and Thornton and Ross Ltd (Huddersfield, UK) during the conduct of the study. Lelia Duley reports grants from the NIHR Clinical Trials Unit support funding during the conduct of the study. Robert Ellis reports personal fees from AMLo Biosciences Ltd (Newcastle upon Tyne, UK) and AbbVie Inc. outside the submitted work. Adam Ferguson reports non-financial support from the National Institute for Health Research (NIHR) during the conduct of the study. John Ingram reports personal fees from UCB Pharma (Brussels, Belgium), Novartis Pharmaceuticals and AbbVie Inc. outside the submitted work. Tracey H Sach was a member of the NIHR Health Technology Assessment (HTA) Commissioning Board (September 2017–January 2020), a member of the NIHR HTA General Funding Board (November 2016–September 2017) and a core member of the NIHR HTA Themed Calls Funding Board (2013–2016). Shyamal Wahie reports non-financial support from Janssen Pharmaceutica, AbbVie Inc., Novartis Pharmaceuticals and Almirall SA outside the submitted work. Hywel C Williams is Director of the HTA programme and chairperson of the HTA Commissioning Board (September 2015–October 2020). From 1 January 2016 he became Programme Director for the HTA programme. He reports grants from NIHR HTA during the conduct of the study and is a member of the HTA Clinical Evaluation and Trials Committee, although he had no role in the decision to fund this study. Alan A Montgomery reports grants from NIHR (Infrastructure Award CTU-26 and NIHR132545) during the conduct of the study.